Skip to main content

Advertisement

SpringerLink
Log in

Multidrug resistance strength of the novel multidrug resistance gene HA117: compared with MRP1

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

The novel gene HA117 is a multidrug resistance (MDR) gene in all-trans retinoic acid resistance HL-60 cells. The transduction of adenovirus vectors encoding HA117 conferred breast cancer cell line 4T1 MDR not only to MRP1 substrate drugs but also to MRP1 non-substrate drugs and the MDR strength of HA117 was similar to that of multidrug resistance-associated protein-1 (MRP1) for MRP1 substrate, but HA117 had no daunorubicin-excretion function.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Zheng GH, Fu JR, Xu YH, et al. Screening and cloning of multi-drug resistant genes in HL-60/MDR cells. Leuk Res. 2009;33(8):1120–3.

    Article  PubMed  CAS  Google Scholar 

  2. Guo Y, Zheng G, Jin X, et al. HA117 gene increased the multidrug resistance of K562 cells in vitro: an investigation to the function of a novel gene related to drug resistance. J Exp Clin Cancer Res. 2009;28:63.

    Article  PubMed  Google Scholar 

  3. Luo J, Deng ZL, Luo X, et al. A protocol for rapid generation of recombinant adenoviruses using the AdEasy system. Nat Protoc. 2007;2(5):1236–47.

    Article  PubMed  CAS  Google Scholar 

  4. Klein I, Sarkadi B, Váradi A. An inventory of the human ABC proteins. Biochim Biophys Acta. 1999;1461(2):237–62.

    Article  PubMed  CAS  Google Scholar 

  5. Doyle LA, Yang W, Abruzzo LV, et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci U S A. 1998;95(26):15665–70.

    Article  PubMed  CAS  Google Scholar 

  6. Goda K, Bacsó Z, Szabó G. Multidrug resistance through the spectacle of P-glycoprotein. Curr Cancer Drug Targets. 2009;9(3):281–97.

    Article  PubMed  CAS  Google Scholar 

  7. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta. 1976;455(1):152–62.

    Article  PubMed  CAS  Google Scholar 

  8. Shikawa T, Nakagawa H. Human ABC transporter ABCG2 in cancer chemotherapy and pharmacogenomics. J Exp Ther Oncol. 2009;8(1):5–24.

    Google Scholar 

  9. Higgins CF. ABC transporters: physiology, structure and mechanism–an overview. Res Microbiol. 2001;152(3–4):205–10.

    Article  PubMed  CAS  Google Scholar 

  10. Fine RL, Chambers TC, Sachs CW. P-Glycoprotein, multidrug resistance and protein kinase C. Oncologist. 1996;1(4):261–8.

    PubMed  CAS  Google Scholar 

  11. Warrell RP Jr, Frankel SR, Miller WH Jr, et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med. 1991;324(20):1385–93.

    Article  PubMed  Google Scholar 

  12. Shen ZX, Shi ZZ, Fang J, et al. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. J Proc Natl Acad Sci U S A. 2004;101(15):5328–35.

    Article  CAS  Google Scholar 

  13. Bellos F, Mahlknecht U. Valproic acid and all-trans retinoic acid: meta-analysis of a palliative treatment regimen in AML and MDS patients. Onkologie. 2008;31(11):629–33.

    Article  PubMed  CAS  Google Scholar 

  14. Gallagher RE. Retinoic acid resistance in acute promyelocytic leukemia. Leukemia. 2002;16(10):1940–58.

    Article  PubMed  CAS  Google Scholar 

  15. Lo Coco F, Ammatuna E, Sanz MA. Current treatment of acute promyelocytic leukemia. Haematologica. 2007;92(3):289–91.

    Article  PubMed  Google Scholar 

  16. Zhou DC, Kim SH, Ding W, et al. Frequent mutations in the ligand-binding domain of PML–RARalpha after multiple relapses of acute promyelocytic leukemia: analysis for functional relationship to response to all-trans retinoic acid and histone deacetylase inhibitors in vitro and in vivo. Blood. 2002;99(4):1356–63.

    Article  PubMed  CAS  Google Scholar 

  17. Wang S, Tricot G, Shi L, et al. RARalpha2 expression is associated with disease progression and plays a crucial role in efficacy of ATRA treatment in myeloma. Blood. 2009;114(3):600–7.

    Article  PubMed  CAS  Google Scholar 

  18. Heuser M, Argiropoulos B, Kuchenbauer F, et al. MN1 overexpression induces acute myeloid leukemia in mice and predicts ATRA resistance in patients with AML. Blood. 2007;110(5):1639–47.

    Article  PubMed  CAS  Google Scholar 

  19. Komura N, Ikeda Y, Masuda N, et al. Designed ATRA analogue active against ATRA-resistant acute promyelocytic leukemia cells having a single nucleotide substitution in their retinoic acid receptor. Leuk Res. 2007;31(3):301–13.

    Article  PubMed  CAS  Google Scholar 

  20. Naoki T, Sumio M, Chihiro K, et al. The possibility of simvastatin as a chemotherapeutic agent for all-trans retinoic acid-resistant promyelocytic leukemia. Biol Pharm Bull. 2008;31(3):369–74.

    Article  Google Scholar 

  21. Herst PM, Hesketh EL, Ritchie DS, et al. Glycolytic metabolism confers resistance to combined all-trans retinoic acid and arsenic trioxide-induced apoptosis in HL60rho0 cells. Leuk Res. 2008;32(2):327–33.

    Article  PubMed  CAS  Google Scholar 

  22. Zang G, Miao L, Mu Y, et al. Adenoviral mediated transduction of adenoid cystic carcinoma by human TRAIL gene driven with hTERT tumor specific promoter induces apoptosis. Cancer Biol Ther. 2009;8(10):966–72.

    Article  PubMed  CAS  Google Scholar 

  23. Campos SK, Barry MA. Current advances and future challenges in Adenoviral vector biology and targeting. Curr Gene Ther. 2007;7(3):189–204.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This work was supported by the National Natural Science Foundation of China (No. 39970768) and in part by the National Natural Science Foundation of China (No. 30330590). We thank Professor Tong-Chuan He (Laboratory of Molecular Oncology, University of Chicago, USA) for providing us the generous gift HEK 293 cell line.

Disclosure statement

We promise that the article is original, is not under consideration, or has not been published previously elsewhere, and its content has not been anticipated by a previous publication. There are no benefits conflicts in any form.

Author information

Authors and Affiliations

  1. Laboratory of Oncology, Affiliated Children’s Hospital, Chongqing Medical University, No.136, Zhongshan 2nd Road Yuzhong District, Chongqing, 86 400014, China

    Lihua Zhao, Yanhui Sun, Xiaoqing Li, Xianqing Jin, Zhenhua Guo, Rui Liang, Xionghui Ding, Tingfu Chen & Siqi Wang

  2. Department of Surgery, Affiliated Children’s Hospital, Chongqing Medical University, No.136, Zhongshan 2nd Road Yuzhong District, Chongqing, 86 400014, China

    Xianqing Jin

  3. Department of Hematology, Affiliated Children’s Hospital, Chongqing Medical University, No.136, Zhongshan 2nd Road Yuzhong District, Chongqing, 86 400014, China

    Youhua Xu

Authors
  1. Lihua Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yanhui Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xiaoqing Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xianqing Jin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Youhua Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Zhenhua Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Rui Liang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Xionghui Ding
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Tingfu Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Siqi Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Xianqing Jin.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zhao, L., Sun, Y., Li, X. et al. Multidrug resistance strength of the novel multidrug resistance gene HA117: compared with MRP1. Med Oncol 28, 1188–1195 (2011). https://doi.org/10.1007/s12032-010-9624-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12032-010-9624-y

Keywords

Search

Navigation